Phase III trial of infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first line treatment in advanced colorectal carcinoma (ACRC): Results of an interim safety analysis.

被引：0
|
作者：
Arkenau, HT
Schmoll, H
Kubicka, S
Seufferlein, T
Reichardt, P
Freier, W
Graeven, U
Grothey, A
Porschen, R
机构：
[1] Cent Hosp Bremen E, Bremen, Germany
[2] Univ Halle Wittenberg, Halle Saale, Germany
[3] Hannover Med Sch, D-3000 Hannover, Germany
[4] Univ Clin Ulm, Ulm, Germany
[5] Charite Berlin, Berlin, Germany
[6] Private Oncol Clin, Hildesheim, Germany
[7] Ruhr Univ Bochum, D-4630 Bochum, Germany
[8] Mayo Clin, Rochester, MN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3546
引用
收藏
页码：256S / 256S
页数：1
相关论文
共 50 条
  • [1] Infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus Capecitabine plus oxaliplatin (CAPOX) as first line treatment of metastatic colorectal carcinoma (MCRC): results of the safety and efficacy analysis
    Arkenau, H.
    Kubicka, S.
    Greil, R.
    Schmoll, H.
    Seufferlein, T.
    Greaven, U.
    Grothey, A.
    Kretschmar, A.
    Hinke, A.
    Porschen, R.
    EJC SUPPLEMENTS, 2005, 3 (02): : 168 - 168
  • [2] Infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first line treatment of metastatic colorectal carcinoma (MCRC): results of a safety and efficacy analysis
    Arkenau, HT
    Schmoll, H
    Kubicka, S
    Kretzschmar, A
    Freier, W
    Seufferlein, T
    Graeven, U
    Grothey, A
    Hinke, A
    Porschen, R
    ANNALS OF ONCOLOGY, 2005, 16 : 283 - 283
  • [3] Phase III trial of infusional 5-fluorouracil/folinic acid plus oxalipiatin (FUFOX) versus capecitabine plus oxalipiatin (CAPOX) as first line treatment of advanced colorectal carcinoma (ACRC): results of an interim efficacy and safety analysis
    Arkenau, Hendrik T.
    Kubicka, S.
    Grall, R.
    Seufferlein, T.
    Freier, W.
    Graeven, U.
    Grothey, A.
    Hinke, A.
    Schmoll, H.
    Porschen, R.
    ANNALS OF ONCOLOGY, 2004, 15 : 72 - 72
  • [4] Infusiorial 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first line treatment of metastatic colorectal cancer (MCRC): Results of the safety and efficacy analysis.
    Arkenau, HT
    Schmoll, H
    Kubicka, S
    Kretzschmar, A
    Freier, W
    Seufferlein, T
    Graeven, U
    Grothey, A
    Hinke, A
    Porschen, R
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 247S - 247S
  • [5] Final results of a randomized comparison of infusional 5-fluorouracil/leucovorin plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) in metastatic colorectal carcinoma (MCRC)
    Porschen, Rainer
    Kubicka, S.
    Grothey, A.
    Grateven, U.
    Kretzschmar, A.
    Greil, R.
    Freier, W.
    Seufferlein, T.
    Arkenau, Ht
    Hinke, A.
    Schmoll, Hj
    Schmiegel, W.
    GASTROENTEROLOGY, 2006, 130 (04) : A582 - A582
  • [6] Phase III trial of irinotecan plus infusional 5-fluorouracil/folinic acid versus irinotecan plus oxaliplatin as first-line treatment of advanced colorectal cancer
    von Weikersthal, Ludwig Fischer
    Schalhorn, Andreas
    Stauch, Martina
    Quietzsch, Detlef
    Maubach, Peter A.
    Lambertz, Helmut
    Oruzio, Daniel
    Schlag, Rudolf
    Weigang-Koehler, Karin
    Vehling-Kaiser, Ute
    Schulze, Manfred
    Truckenbrodt, Juergen
    Goebeler, Mariele
    Mittermueller, Johann
    Bosse, Daniel
    Szukics, Borika
    Grundeis, Marc
    Zwingers, Thomas
    Giessen, Clemens
    Heinemann, Volker
    EUROPEAN JOURNAL OF CANCER, 2011, 47 (02) : 206 - 214
  • [7] Phase III study of 5-fluorouracil/leucovorin plus oxaliplatin versus capecitabine plus oxaliplatin as first line therapy in patients with advanced colorectal cancer (ACRC)
    Porschen, R
    Arkenau, T
    Kubicka, S
    Schmoll, HJ
    Seufferlein, T
    Graeven, U
    Grothey, A
    GASTROENTEROLOGY, 2005, 128 (04) : A438 - A438
  • [8] Protracted 5-fluorouracil infusion plus oxaliplatin (FOX) versus capecitabine plus oxaliplatin (XELOX) as first-line treatment in advanced colorectal cancer (ACRC): Preliminary results of the Italian phase IIFOCA study
    Martoni, Andrea
    Pinto, Carmine
    Di Fabio, Francesca
    Lelli, Giorgio
    Llimpe, Fabiola Lorena Rojas
    Gentile, Anna Lisa
    Mutri, Vita
    Ballardini, Pierluigi
    Giaquinta, Stefania
    Piana, Edera
    ANNALS OF ONCOLOGY, 2005, 16 : 47 - 47
  • [9] Phase II randomized trial on protracted 5-fluorouracil infusion plus oxaliplatin (FOX) versus capecitabine plus oxaliplatin (XELOX) as first-line treatment in advanced colorectal cancer (ACRC): Preliminary results of the Italian FOCA study.
    Martoni, A
    Pinto, C
    Di Fabio, F
    Lelli, G
    Gentile, AL
    Llimpe, FLR
    Mutri, V
    Ballardini, PL
    Giaquinta, S
    Piana, E
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 275S - 275S
  • [10] Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer
    Cassidy, Jim
    Clarke, Stephen
    Diaz-Rubio, Eduardo
    Scheithauer, Werner
    Figer, Arie
    Wong, Ralph
    Koski, Sheryl
    Lichinitser, Mikhail
    Yang, Tsai-Shen
    Rivera, Fernando
    Couture, Felix
    Sirzen, Florin
    Saltz, Leonard
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (12) : 2006 - 2012
12345